Look up any medication against Foundayo, Mounjaro, Zepbound, Ozempic or Wegovy. Each entry carries a severity tier and names its source: the FDA prescribing-information section where a label covers it, or the study or review where none does. The database holds 18 interactions at present.
Filter by severity
18 of 18 entries shown, each one citing the FDA prescribing information section it came from. This is educational material and replaces neither pharmacist nor prescriber.
Section 1 (Limitations of Use) of the Wegovy, Zepbound and Foundayo labels each advise against pairing the drug with a second GLP-1 receptor agonist (their wording: "not recommended"). The Ozempic and Mounjaro labels carry no such sentence, but there is no clinical case for stacking two drugs aimed at the same receptor, and what stacks up if you try it — GI side effects, and hypoglycemia where T2D is present — argues against it.
What to do
Never run the two together. To change drugs, stop the first and begin the second at its lowest dose on what would have been the next injection day — that is the ordinary switching guidance used in practice. A full pharmacokinetic washout is a separate matter: it lasts 5 half-lives, roughly 25 days for tirzepatide, roughly 35 days for semaglutide. Our washout calculator at /tools/glp1-washout-calculator uses those figures, because planning around surgery or pregnancy is a different question from switching drugs.
Mechanism
One receptor, two drugs aimed at it. Nothing extra is gained in efficacy; what doubles is receptor activation, and with it the side effects.
Insulin taken alongside a GLP-1 receptor agonist makes hypoglycemia — blood sugar falling too low — more likely, and the escalation weeks are when it is likeliest.
What to do
Each of the five labels tells prescribers to weigh a lower insulin or secretagogue dose at the point the GLP-1 begins ("consider reducing the dose"), so that blood sugar is less likely to crash. The labels give no fixed percentage, so how much is your prescriber's call. Agree it with them BEFORE the first GLP-1 dose, and watch blood glucose closely from there. The Wegovy label adds that Wegovy in combination with insulin "has not been evaluated".
Mechanism
A GLP-1 receptor agonist already pushes insulin secretion up in a glucose-dependent way while pulling glucagon down. Injected insulin lands on top of that, and the hypoglycemic risk adds together.
Put a sulfonylurea together with a GLP-1 receptor agonist and hypoglycemia becomes substantially more likely.
What to do
On a sulfonylurea — glimepiride, glyburide, glipizide — expect your prescriber to cut that dose as the GLP-1 begins. Some people come off the sulfonylurea altogether. Either way, keep a close watch on blood glucose.
Mechanism
A sulfonylurea drives insulin out whatever the glucose level happens to be. The GLP-1 then adds its own glucose-dependent boost. In the labeled trials, hypoglycemia (below 54 mg/dL) struck 10.3% of Zepbound users who also took a sulfonylurea, against 2.1% of Zepbound users without one (Zepbound PI 5.7), and in 7% versus 0.5% on Foundayo (Foundayo PI 5.5).
FOUNDAYO (orforglipron) alone is affected here; the Wegovy, Ozempic, Mounjaro and Zepbound labels set no CYP3A4 rule. Because CYP3A4 metabolizes Foundayo, a strong inhibitor of that enzyme pushes Foundayo levels up (clarithromycin raised Foundayo AUC 3.5-fold in the labeled study), and a strong inducer can pull them down far enough to cost you the effect (carbamazepine cut AUC by 82%).
What to do
The Foundayo label sets four rules. With a strong CYP3A4 inhibitor (the label's studied example is clarithromycin), "The maximum dosage of FOUNDAYO is 9 mg once daily." With a strong CYP3A4 inhibitor which blocks OATP1B as well, AVOID the combination outright: the label names ritonavir, and cobicistat inhibits OATP1B1/1B3 according to its own label. With a strong CYP3A4 inducer (the label's studied example is carbamazepine), AVOID. With a moderate inducer (the label's modeled example: efavirenz), the label asks your prescriber to keep checking that Foundayo still works and to step the dose up if it does not. Ask your pharmacist which group your drug is in. None of this reaches Wegovy, Ozempic, Mounjaro or Zepbound.
Mechanism
Orforglipron, an oral small-molecule GLP-1 receptor agonist, "is metabolized primarily via hepatic CYP3A4" and is also a substrate of the OATP1B1 and OATP1B3 transporters, which is why a drug that inhibits both raises exposure further. Inhibit CYP3A4 and exposure rises; induce it and exposure falls. The semaglutide and tirzepatide labels report low potential for CYP interactions and set no CYP3A4 dosing rule.
Warfarin
Anticoagulant
Moderate — be aware
Common brand names
Coumadin · Jantoven
Clinical effect
With the stomach emptying more slowly, warfarin may be absorbed at a different rate and INR may shift with it. In practice the effect is usually small, though it varies between people.
What to do
Step up INR monitoring whenever a GLP-1 receptor agonist is started or its dose raised. Changing the warfarin dose is rarely called for, but that call belongs to whoever manages your anticoagulation.
Mechanism
Gastric emptying slows under a GLP-1 receptor agonist. That can delay warfarin absorption while leaving total bioavailability broadly intact.
Oral contraceptives (combined and progestin-only)
Oral contraceptive
Moderate — be aware
Common brand names
Yasmin · Yaz · Loestrin · Lo Loestrin Fe · Microgestin · Sprintec · Tri-Sprintec · Ortho Tri-Cyclen · Necon · Junel · Mononessa · Camila · Errin · Slynd
Clinical effect
Where oral hormonal contraceptives are concerned the drugs part company. Tirzepatide's pharmacokinetic study found contraceptive exposure dropping after the first dose, so the Mounjaro and Zepbound labels carry an explicit FDA directive, and Foundayo (oral orforglipron) carries one of the same kind. Semaglutide does not: the Ozempic and Wegovy labels report NO clinically significant change in levonorgestrel or ethinyl estradiol pharmacokinetics, and no backup contraception is required with it.
What to do
Starting TIRZEPATIDE (Mounjaro or Zepbound) or FOUNDAYO while on oral birth control means following the FDA label: either move to a non-oral method — ring, patch, injection, implant, IUD — or add a barrier method on top. How long depends on the drug. On Foundayo the cover runs 30 days from the start, then a further 30 days from each dose increase. On tirzepatide it is 4 weeks from the start, and 4 weeks again from each dose increase. No such requirement attaches to semaglutide (Wegovy/Ozempic), though your contraception plan is still worth confirming with your prescriber.
Mechanism
Anything taken by mouth can be absorbed more slowly, or less completely, when gastric emptying slows. Tirzepatide's effect is measured and on the label: with a single 5 mg dose, ethinyl estradiol Cmax fell 59% and AUC 20%, and the label notes tirzepatide's effect on gastric emptying was greatest after the first dose and diminished after later ones. For Foundayo the label says its effect on oral contraceptives "has not been evaluated in a clinical trial", so the directive is a precaution. Semaglutide's labeled PK data show nothing clinically relevant. A hormonal contraceptive that is not swallowed is unaffected.
Levothyroxine (thyroid hormone replacement)
Thyroid hormone
Moderate — be aware
Common brand names
Synthroid · Levoxyl · Tirosint · Unithroid
Clinical effect
The Wegovy label, which now covers Wegovy tablets, reports that when levothyroxine was given with the semaglutide tablet in an interaction study, levothyroxine exposure rose by 33% (90% CI: 1.25-1.42). The injection studies found no effect on the oral drugs tested, but every GLP-1 label asks for caution with oral medications because gastric emptying slows.
What to do
Tell your prescriber you take levothyroxine before a GLP-1 starts, and expect your thyroid levels (TSH) to be rechecked after it starts or the dose changes. The Wegovy label says to "Monitor the effects of oral medications" and to consider increased laboratory monitoring for drugs that need it. On Wegovy tablets, the label says to wait at least 30 minutes after the tablet before taking other oral medications. Never change your levothyroxine dose on your own.
Mechanism
The labels put the oral-medication caution down to delayed gastric emptying. The 33% rise was measured with the semaglutide tablet; the labels report no such study with an injectable GLP-1.
Gut motility slows under opioids and under GLP-1 receptor agonists alike, and using both compounds the risk of fecal impaction, severe constipation and ileus. Every FDA-approved GLP-1 label lists those events in Section 6.2, Postmarketing Experience.
What to do
Keep the opioid at the lowest dose that works, and push fluid and fiber up. Four things mean stopping the GLP-1 and getting emergency care straight away: severe constant abdominal pain, persistent vomiting, abdominal distension, or >24 hours with no stool or gas.
Mechanism
Two distinct mechanisms slow motility and they compound: opioid μ-receptor effects on enteric neurons, and GLP-1 receptor agonism on the same neurons. It matters most through early titration, when the GLP-1 GI effects run highest.
Adipose tissue is where benzodiazepines distribute. Lose body weight on a GLP-1 and their volume of distribution can shift, which lets the same dose reach a higher effective plasma concentration. A 2025 review notes that lorazepam's volume of distribution was 1.7-fold lower in non-obese than in obese participants. That is a comparison between groups, not a measured weight-loss change.
What to do
Watch for morning grogginess, impaired balance and deeper sedation, most of all through the rapid-weight-loss phase in months 1-6. If any of that appears, raise a dose reduction with your prescriber — never make the change yourself.
Mechanism
These drugs are strongly lipophilic. Lose fat quickly and the compartment they distribute into shrinks; a smaller distribution volume means the same milligram dose sits at a higher relative plasma concentration.
Acetaminophen (paracetamol)
Analgesic / antipyretic
Minor — generally safe
Common brand names
Tylenol · Panadol · FeverAll
Clinical effect
Acetaminophen may take a little longer to start working. On the tirzepatide labels, a first 5 mg dose cut acetaminophen's peak level by 50-55% and pushed the peak back about 1 hour; by week 4 to 6 there was no meaningful effect, and total exposure (AUC) was not influenced. On the Foundayo label, the first 0.8 mg dose cut acetaminophen's peak by 28%, and the effect faded with repeated dosing.
What to do
Nothing to do differently. Take it as you always have; relief from pain or fever may simply arrive a little later.
Mechanism
Slower gastric emptying delays acetaminophen's peak. The tirzepatide labels report that the effect on gastric emptying was greatest after the first dose and diminished after later doses.
Metformin
Biguanide (oral diabetes medication)
Minor — generally safe
Common brand names
Glucophage · Glumetza · Fortamet · Riomet
Clinical effect
The pair is generally well tolerated. Both bring the same GI side effects — diarrhea, nausea — and in the opening weeks of GLP-1 therapy those can stack.
What to do
Stay on metformin as prescribed. Expect diarrhea and nausea to be temporarily worse while the GLP-1 dose is ramping. Neither drug usually needs its dose changed.
Mechanism
Two unrelated mechanisms. Metformin activates AMPK and cuts hepatic glucose production; the GLP-1 raises glucose-dependent insulin secretion. GI side effects arise from each on its own.
None of the semaglutide or tirzepatide labels restricts a statin. Semaglutide PK studies found no clinically relevant change in atorvastatin (Ozempic label) or rosuvastatin (Wegovy label). FOUNDAYO (orforglipron) breaks the pattern: it doubled exposure of simvastatin's active form, simvastatin acid, and the label caps the simvastatin dose accordingly.
What to do
On semaglutide or tirzepatide, nothing changes: carry on with the statin as prescribed. On FOUNDAYO, simvastatin stops at 20 mg once daily and must go no higher; no other statin has a labeled dose limit. Confirm the dose with your prescriber as Foundayo starts.
Mechanism
Foundayo acts on the other drug: "Use of FOUNDAYO with simvastatin increased exposure of the active metabolite simvastatin acid two-fold", which "at the highest simvastatin dose could be clinically meaningful." The Foundayo label also reports smaller rises for atorvastatin (AUC 1.5-fold) and rosuvastatin (1.7-fold) but sets no dose rule for them.
ACE inhibitors and ARBs (blood pressure medications)
No interaction as such. The GLP-1-induced weight loss tends to bring blood pressure down a little on its own, and that adds to whatever the antihypertensive is already doing.
What to do
Keep taking your blood pressure medication as prescribed, but watch for the signs of it running too low — lightheadedness when you stand. As the weight comes off, the dose may need reducing.
Mechanism
Blood pressure falls with weight loss on its own account. Stack that on antihypertensive therapy and hypotension is an occasional result.
No drug interaction as such. The EMA's safety committee (PRAC) found in April 2024 that the evidence on semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide did not support a causal link with suicidal or self-harm thoughts and actions, and in February 2026 the warning on Suicidal Behavior and Ideation came off both the Wegovy label and the Zepbound label.
What to do
Stay on the antidepressant as prescribed. Where there is a history of depression, keep active track of mood through the first 8-12 weeks on a GLP-1, and take anything that shifts to your mental health provider as well as your prescriber.
Mechanism
The mechanisms are unrelated, and no pharmacokinetic interaction has been documented.
No drug interaction as such, and the pairing may work in your favor: acid reflux is something a GLP-1 receptor agonist can bring on or aggravate, and managing it is exactly what PPIs/H2 blockers do.
What to do
Carry on with it, or start it, as reflux symptoms require. Take reflux that is severe or will not settle to your prescriber.
Mechanism
GERD can worsen under GLP-1-induced slowing of gastric emptying; suppressing acid treats the symptom that results.
Slowed gastric emptying may delay NSAID absorption, so pain relief can start later. We found no study that has measured NSAID levels with any GLP-1; this rests on the labels' general caution about oral medications.
What to do
Take it as prescribed, and keep an eye out for NSAID-related GI effects that seem out of the ordinary — during titration they add to what the GLP-1 is already doing. Ongoing pain that needs an NSAID is worth a conversation with your prescriber about dose and timing.
Mechanism
The absorption of an NSAID taken by mouth can shift when gastric emptying is delayed. How much, if at all, has not been measured.
The rate at which an oral antibiotic is absorbed can change under GLP-1-induced gastric emptying delay. No study has measured how much; with some agents, onset may simply arrive later.
What to do
Take it as prescribed and finish the course. Should vomiting or severe nausea on the GLP-1 stop you keeping doses down, tell your prescriber promptly: an underdosed antibiotic invites antimicrobial resistance and treatment failure.
Mechanism
Every GLP-1 label carries a class-level caution (Section 7.2; Section 7.3 on Foundayo) covering any oral medication given alongside a drug that delays gastric emptying. No PK study specific to antibiotics has been published.
For anyone on long-term antipsychotic therapy, a GLP-1 receptor agonist works against the weight gain those drugs cause. Several systematic reviews back the combination, and nobody has reported a pharmacokinetic interaction between the two that matters clinically.
What to do
Stay on both, supervised by your prescriber. Antipsychotic efficacy is not reduced by the GLP-1, which meanwhile blunts the weight gain. Keep the prescribing psychiatrist or PCP in the loop.
Mechanism
What the GLP-1 does to appetite and gastric emptying runs against the appetite stimulation and weight gain of an atypical antipsychotic. Different physiological pathways, and no pharmacokinetic interference between them.
How to read the severity tiers
Contraindicated — Do not combine. The combination is explicitly contraindicated by the FDA label. No entry in the database sits in this tier at present; combining two GLP-1 receptor agonists, which the Wegovy, Zepbound and Foundayo labels call “not recommended”, is listed as Serious.
Serious — you may combine them, but only with close monitoring, or with one drug's dose adjusted in advance. Insulin and the sulfonylureas are the standard case: both can drive hypoglycemia, so the labels tell prescribers to consider lowering the existing diabetes medication when the GLP-1 starts.
Moderate — Be aware. The interaction is real but usually does not require dose adjustment. Often involves slowed gastric emptying changing how an oral medication is absorbed; sometimes total exposure shifts too (levothyroxine rose 33% with the semaglutide tablet). Examples: warfarin, levothyroxine, oral contraceptives.
Minor — Generally no action needed. Either no documented interaction or the effect is clinically irrelevant (e.g., the roughly 1-hour delay in acetaminophen's peak after a first tirzepatide dose).
Why GLP-1s have so many gastric-emptying interactions
GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action — that's a major contributor to the satiety effect that produces weight loss. The same mechanism can delay the absorption of medications taken by mouth, which is why every one of these labels asks for caution with oral medications. In the labeled studies the effect was usually small: after a first tirzepatide dose, acetaminophen peaked about 1 hour later with total exposure (AUC) unchanged, and semaglutide injection did not affect the oral drugs tested to any clinically relevant degree. Exceptions exist: levothyroxine exposure rose 33% with the semaglutide tablet, and tirzepatide lowered oral contraceptive levels. The labels ask for closer monitoring of drugs with a narrow therapeutic index, such as warfarin.
Hypoglycemia risk with insulin and sulfonylureas
The most clinically important GLP-1 interaction is the additive hypoglycemia risk when combined with insulin or a sulfonylurea (glipizide, glyburide, glimepiride). GLP-1s enhance glucose-dependent insulin secretion — meaning they only push insulin when blood sugar is elevated — but adding insulin or a sulfonylurea on top can produce dangerous lows. Every one of the five labels tells prescribers to consider reducing the dose of insulin or the insulin secretagogue when the GLP-1 is started. The labels set no fixed percentage, so the size of the cut is your prescriber's call. Discuss it with them before the first GLP-1 dose, not after the fact.
Oral contraceptives: a labeled warning on Foundayo and on tirzepatide
Which GLP-1 you are on decides what the FDA label asks of you here.Tirzepatide (Mounjaro and Zepbound) carries an explicit Section 7 directive: move to a non-oral method — ring, patch, injection, implant or IUD — or add a barrier method, holding that for 4 weeks from the start, then 4 weeks from every dose increase. Foundayo (orforglipron, the oral GLP-1) asks the same thing on a longer clock: 30 days from the start, and 30 days from every dose increase. Semaglutide (Wegovy and Ozempic) is the exception — its label reports no clinically significant change in oral contraceptive (ethinyl estradiol/levonorgestrel) levels, so it does not require backup contraception. The tirzepatide and Foundayo labels say hormonal contraceptives not taken by mouth should not be affected. If you take oral birth control and are starting tirzepatide or Foundayo, discuss a backup strategy with your prescriber before your first dose.
What this tool is NOT
It is a lookup tool for learning from, and nothing more. It is not clinical decision support, not a replacement for your pharmacist or prescriber, and not the real-time checker built into an electronic health record. What the database holds are the clinically meaningful interactions that come up most often — not all of them. Tell every pharmacist and every prescriber everything you take, supplements and over-the-counter products included, and check any specific interaction with them before you start or stop anything.
References
1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, Recent Major Changes and Sections 1, 2.1, 5.4, 6.2, 7 and 12.3. DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, SPL version 19 (published June 30, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
3.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Recent Major Changes and Sections 1, 5.7, 6.2, 7 and 12.3. DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, SPL version 40 (published September 2, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
5.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Sections 1, 2.2, 5.5, 6.2, 7, 8.3 and 12.3. DailyMed SetID 8ac446c5-feba-474f-a103-23facb9b5c62, SPL version 10 (published August 13, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
6.Gilead Sciences, Inc. TYBOST (cobicistat) tablets — US Prescribing Information, Section 7.1 (transporters inhibited, including OATP1B1 and OATP1B3). DailyMed SetID 3784c35c-e87f-410c-900b-8fd6313c6010, SPL version 16 (published February 18, 2026). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3784c35c-e87f-410c-900b-8fd6313c6010
7.Hooper L, Liu S, Pai MP. GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis. Pharmacotherapy. 2025. PMID: 39989027.
8.Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development and Therapy. 2025. PMID: 40330819.
Side-effect timeline tool — which week each side effect peaks in and when it settles, drug by drug. Useful when another medication changes and your tolerability moves with it.
Important disclaimer
Educational material, not medical advice. What an interaction does to you turns on your dose, your timing and everything else on your medication list, which makes it an individual matter. GLP Watchdog gives no diagnosis, no treatment recommendation and no medical advice. Before any medication joins a GLP-1 receptor agonist, put it to your pharmacist and your prescribing clinician.
Alcohol has its own write-up, drinking on a GLP-1, built from the same labels.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
7.4
Wellorithm
Compounded semaglutide at a flat $247 every 28 days, any dose